Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3853 participants.
Also called NCT07173855
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,853 participants
- Sponsor
- Registry
-
NCT07173855
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT07173855. Randomized; no masking; primary purpose treatment. Start 2025-11-25 (actual); primary completion 2027-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
- Acronym
- MAGNOLIA
- Condition
- Critical Illness
- Intervention (Drug)
- Magnesium sulfate administration
- Intervention (Drug)
- Magnesium oxide
- Intervention (Drug)
- Magnesium glucoheptonate
- Lead sponsor
- Scarborough General Hospital
- Collaborator
- Scarborough Health Network
- Collaborator
- Lakeridge Health Corporation
Record details
- Record id
cardio:ct-nct07173855- Content hash
a7553aef0616a41088f63ee846c166f2fac695682fa01ad7c5be362f6e3ac728